The First to File studies basically recognize a company for manufacturing the generic version of a drug after the patent has expired. A marketing exclusivity of 180 days is also given from the date of approval of Abbreviated New Drug Application (ANDA), thus offering the manufacturers a substantial cost advantage.

At VIMTA, we have helped several clients with first to file studies in record time.